Alofropodect Met Primary Endpoints in Clinical Trial
The experimental schizophrenia treatment showed positive results in a recent phase 2 clinical study.
Updated on Sept. 29, 2026 in Mental Health
Live Poll
Do you trust that new clinical trial results for schizophrenia treatments represent significant medical progress?
Alofropodect, a phosphodiesterase 10A inhibitor, met its primary endpoints in a phase 2 clinical trial involving 189 hospitalized adult patients with acute schizophrenia. Participants showed significant improvements in PANSS positive subscale scores after four weeks of daily treatment.
Why it matters
PDE10A inhibition targets the basal ganglia to potentially offer a new mechanism for treating schizophrenia symptoms. This approach aims to address treatment gaps while avoiding metabolic side effects common in other antipsychotic medications.
In a 189-patient trial, the 40 mg dosage of alofropodect achieved a -6.35 change in PANSS positive subscale scores, significantly outperforming the 3.8% response rate observed in the placebo group.
The players
Celon Pharma
This pharmaceutical company conducts research into novel drug therapies, including the development of alofropodect in Poland.
University of Rhode Island
This academic institution maintains a research presence in Kingston, Rhode Island, contributing to broader scientific discourse.
The details
Patients underwent a medication washout period of up to 7 days before starting a daily regimen of oral alofropodect or a placebo for 4 weeks. While active treatment resulted in reports of somnolence and extrapyramidal symptoms, patients did not experience increases in triglycerides, total cholesterol, or blood glucose levels.
Timeline
The PDE10A enzyme expression in the striatum was initially determined in 1999.
Several previous clinical trials for PDE10A inhibitors failed between 2017 and 2019.
Menniti et al published an analysis regarding lessons from failed trials in 2021.
The final PANSS primary endpoint assessment was conducted at week 4.
The Big Picture
This study marks a potential departure from the historical pattern of failure documented in the 2021 Menniti et al analysis.
Patients may eventually see a new treatment option that avoids the metabolic side effects, such as elevated blood glucose, associated with current antipsychotic drugs. However, potential side effects like somnolence will remain a factor for clinicians to monitor during treatment.
The takeaway
This phase 2 success offers a promising signal for targeting the PDE10A enzyme in the treatment of schizophrenia. Further research will be essential to confirm if these results can be replicated in larger, long-term patient populations.
Further reading
For more information on current treatment landscapes, visit Mental Health.
Source note: This article includes information reported by Psychiatrictimes.
Live Poll
Do you trust that new clinical trial results for schizophrenia treatments represent significant medical progress?
